Yolk–Shell Nanostructure: An Ideal Architecture to Achieve Harmonious Integration of Magnetic–Plasmonic Hybrid Theranostic Platform
Source abstract
Abstract
Magnetic–plasmonic hybrid nanoparticles (MPHNs) have attracted great interest in cancer theranostics. However, the relaxivity of the magnetic component is typically reduced by the plasmonic component in conventional core–shell structured MPHNs, due to the presence of a water‐impenetrable coating which severely restricts the proximity of protons to the magnetic portion. To circumvent this issue, yolk–shell structured MPHNs comprising a Fe3O4 core within a hollow cavity encircled by a porous Au outer shell are designed. As expected, the introduction of hollow cavity between the magnetic and plasmonic portions significantly prevents the decline in relaxivity of the Fe3O4 core caused by the Au layer. Moreover, in addition to conferring high near‐infrared absorption to plasmonic component, the hollow cavity and the pores in the outer shell can also provide a large storage space and release channels for anticancer drugs. Furthermore, the multicomponent nanoparticles (NPs) still have a compact size of less than 100 nm to ensure efficient tumor accumulation. Taken together, the yolk–shell Fe3O4@Au NPs can be regarded as an ideal magnetic–plasmonic theranostic platform for magnetic resonance/photoacoustic/positron emission tomography multimodal imaging and light‐activated chemothermal synergistic therapy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Gold and Silver Nanoparticles Synthesis and Applications · Nanoparticle-Based Drug Delivery · Characterization and Applications of Magnetic Nanoparticles
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
The Key Lab of Analysis and Detection Technology for Food Safety of the MOE College of Chemistry Fuzhou University Fuzhou 350108 China
Laboratory of Molecular Imaging and Nanomedicine (LOMIN) National Institute of Biomedical Imaging and Bioengineering (NIBIB) National Institutes of Health (NIH) Bethesda MD 20892 USA
Funding
National Natural Science Foundation of China · Natural Science Foundation of Fujian Province · National Institute of Biomedical Imaging and Bioengineering
References (32)
Show source-provided references
1. 10.1021/ar400086e10.1021/ar400086e ↗
2. 10.1021/cr500537t10.1021/cr500537t ↗
3. 10.1002/adfm.20120146910.1002/adfm.201201469 ↗
4. 10.1021/nn500722y10.1021/nn500722y ↗
5. 10.1002/adma.20110496410.1002/adma.201104964 ↗
6. 10.1039/C1CS15213K10.1039/C1CS15213K ↗
7. 10.1002/anie.20060247110.1002/anie.200602471 ↗
8. 10.1002/adma.20110352110.1002/adma.201103521 ↗
9. 10.1038/nrd261410.1038/nrd2614 ↗
10. 10.1021/ja073057v10.1021/ja073057v ↗
11. 10.1002/anie.20130224510.1002/anie.201302245 ↗
12. 10.1002/anie.20150467610.1002/anie.201504676 ↗
13. 10.1016/j.biomaterials.2014.10.06510.1016/j.biomaterials.2014.10.065 ↗
14. 10.1038/ncomms104210.1038/ncomms1042 ↗
15. 10.1021/ja504118q10.1021/ja504118q ↗
16. 10.1002/adma.20150194210.1002/adma.201501942 ↗
17. 10.1021/nl102623x10.1021/nl102623x ↗
18. 10.1021/nn503865210.1021/nn5038652 ↗
19. 10.1021/cm302828d10.1021/cm302828d ↗
20. 10.1002/adma.20160248610.1002/adma.201602486 ↗
21. 10.1021/jz402795x10.1021/jz402795x ↗
22. 10.1021/acs.nanolett.6b0086810.1021/acs.nanolett.6b00868 ↗
23. 10.1021/acs.chemrev.5b0011210.1021/acs.chemrev.5b00112 ↗
24. 10.1103/PhysRevLett.102.08660110.1103/PhysRevLett.102.086601 ↗
25. 10.1038/nmat256410.1038/nmat2564 ↗
26. 10.1002/advs.20160010610.1002/advs.201600106 ↗
27. 10.1002/adma.20150567810.1002/adma.201505678 ↗
28. 10.1039/C2CS15261D10.1039/C2CS15261D ↗
29. 10.1002/smll.20150073510.1002/smll.201500735 ↗
30. 10.1039/B709883A10.1039/B709883A ↗
31. 10.1021/ja505412p10.1021/ja505412p ↗
32. 10.1002/adma.20150248610.1002/adma.201502486 ↗